These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24161296)

  • 1. [Peripartum period and hemophilia carriers].
    Bonnet A; Chevalier Y; Wallon G; Huissoud C; Aubrun F
    Ann Fr Anesth Reanim; 2013 Nov; 32(11):807-10. PubMed ID: 24161296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding symptoms in carriers of hemophilia A and B.
    Mauser Bunschoten EP; van Houwelingen JC; Sjamsoedin Visser EJ; van Dijken PJ; Kok AJ; Sixma JJ
    Thromb Haemost; 1988 Jun; 59(3):349-52. PubMed ID: 2847347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and outcomes of mild hemophiliacs and hemophilia carriers during pregnancy and peripartum period: a hemophilia treatment center experience in the United States.
    Lim HI; DeSancho MT
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):9759-9764. PubMed ID: 35414333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of joint bleeding in hemophilia.
    Simpson ML; Valentino LA
    Expert Rev Hematol; 2012 Aug; 5(4):459-68. PubMed ID: 22992238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Haemophilia].
    Loomans JI; Lock J; Peters M; Leebeek FW; Cnossen MH; Fijnvandraat K
    Ned Tijdschr Geneeskd; 2014; 158():A7357. PubMed ID: 25351381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery and neuraxial technique outcomes in patients with hemophilia and in hemophilia carriers: a systematic review.
    Togioka BM; Burwick RM; Kujovich JL
    J Anesth; 2021 Apr; 35(2):288-302. PubMed ID: 33682038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding in carriers of hemophilia.
    Plug I; Mauser-Bunschoten EP; Bröcker-Vriends AH; van Amstel HK; van der Bom JG; van Diemen-Homan JE; Willemse J; Rosendaal FR
    Blood; 2006 Jul; 108(1):52-6. PubMed ID: 16551972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor IX levels during pregnancy in a women with hemophilia B.
    Briet E; Reisner HM; Blatt PM
    Haemostasis; 1982; 11(2):87-9. PubMed ID: 7084812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation and importance of factor VIII levels in hemophilia A carriers.
    Cygan PH; Kouides PA
    Curr Opin Hematol; 2021 Sep; 28(5):315-322. PubMed ID: 34397591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
    Iizuka A; Kuwashima M; Nagao T
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined factor V and VIII deficiency and pregnancy--need for an early protocol-based multidisciplinary management.
    Hoffmann C; Falzone E; Mihai A; Gitz L; Itzhar-Baikian N; Martel-Jacob S; Mercier FJ
    Ann Fr Anesth Reanim; 2013 Nov; 32(11):e163-5. PubMed ID: 24161289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
    Berntorp E; Shapiro AD; Waters J; Astermark J
    Haemophilia; 2014 Sep; 20(5):e362-4. PubMed ID: 25156443
    [No Abstract]   [Full Text] [Related]  

  • 16. Progress and problems in hemophilia and von Willebrand's disease.
    Abildgaard CF
    Adv Pediatr; 1984; 31():137-77. PubMed ID: 6440429
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pattern of hemophilia and causes of variability.
    Mingot-Castellano ME
    Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S4-S6. PubMed ID: 31517708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
    Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
    Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.
    Owaidah T; Momen AA; Alzahrani H; Almusa A; Alkasim F; Tarawah A; Nouno RA; Batniji FA; Alothman F; Alomari A; Abu-Herbish S; Abu-Riash M; Siddiqui K; Ahmed M; Mohamed SY; Saleh M
    Medicine (Baltimore); 2017 Jan; 96(2):e5456. PubMed ID: 28079788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.